[0232] The present invention is not limited in scope by the specific embodiments described herein. Various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims. Unless otherwise apparent from the context any step, element, embodiment, feature or aspect of the invention can be used in combination with any other. All patent filings, and scientific publications, accession numbers and the like referred to in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if so individually denoted.

1-59. (canceled)

60. A pharmaceutical composition comprising a therapeutically effective amount of a fucose analog selected from the group consisting of one of the following formulae (V) or (VI):

(V)



-continued

(VI)



or a biologically acceptable salt or solvate thereof, wherein each fucose analog of formula (V) or (VI) can be the alpha or beta anomer or the corresponding aldose form;

wherein each of R^1, R^3, and R^4 is independently selected from the group consisting of —OH and —$OC(O)C_1$-C_{10} alkyl; and R^2 is F, R^{2a} and R^{3a} are each H, and R^5 is —CH_3.

61. The pharmaceutical composition of claim **60**, wherein each of R^1, R^3, and R^4 is independently selected from the group consisting of —OH and —OAc, R^2 is F, R^{2a} and R^{3a} are each H, and R^5 is —CH_3.

62. The pharmaceutical composition of claim **60**, wherein the fucose analog is 2-deoxy-2-fluorofucose.

63. The pharmaceutical composition of claim **60**, wherein the fucose analog is 2-deoxy-2-fluorofucose peracetate.

64. The pharmaceutical composition of claim **60**, wherein the composition is suitable for oral administration.

* * * * *